Scpharmaceuticals (NASDAQ:SCPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “

SCPH has been the topic of a number of other research reports. BMO Capital Markets began coverage on Scpharmaceuticals in a research note on Tuesday, December 12th. They set an “outperform” rating and a $24.00 price objective on the stock. Jefferies Group assumed coverage on Scpharmaceuticals in a research report on Tuesday, December 12th. They issued a “buy” rating and a $23.00 target price on the stock. Finally, Leerink Swann assumed coverage on Scpharmaceuticals in a research report on Tuesday, December 12th. They issued an “outperform” rating and a $20.00 target price on the stock.

Scpharmaceuticals (SCPH) opened at $12.46 on Wednesday. Scpharmaceuticals has a 12 month low of $11.50 and a 12 month high of $18.17.

In other Scpharmaceuticals news, major shareholder 5Am Partners Iv, Llc bought 654,762 shares of Scpharmaceuticals stock in a transaction on Tuesday, November 21st. The shares were bought at an average price of $14.00 per share, for a total transaction of $9,166,668.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A number of large investors have recently bought and sold shares of SCPH. Monashee Investment Management LLC purchased a new stake in Scpharmaceuticals in the fourth quarter valued at $230,000. Bank of New York Mellon Corp purchased a new stake in Scpharmaceuticals in the fourth quarter valued at $414,000. Nicholas Investment Partners LP purchased a new stake in shares of Scpharmaceuticals in the 4th quarter valued at $1,500,000. Finally, AWM Investment Company Inc. purchased a new stake in shares of Scpharmaceuticals in the 4th quarter valued at $1,996,000. Institutional investors own 0.07% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Scpharmaceuticals (SCPH) Downgraded to “Sell” at Zacks Investment Research” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://theolympiareport.com/2018/02/14/scpharmaceuticals-scph-downgraded-to-sell-at-zacks-investment-research.html.

Scpharmaceuticals Company Profile

scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.